We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

HAEMONETICS

Haemonetics Corporation’s comprehensive portfolio of devices, information management, and consulting services offers ... read more Featured Products: More products

Download Mobile App




Haemonetics Displays Small, Cartridge-Based TEG 6s Hemostasis Analyzer at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 29 Sep 2021

Haemonetics Corporation (Boston, MA, USA) displayed its small, cartridge-based TEG 6s hemostasis analyzer at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s premier gathering of clinical lab professionals from around the world. More...

Haemonetics provides blood management solutions to help improve care & reduce costs. The company’s TEG 6s system addresses the limitations of traditional testing by delivering fast, comprehensive, & functional assessment of coagulation. The analyzer’s easy-to-use test cartridge delivers a rapid, comprehensive picture of patient hemostasis giving invaluable insight. With a small footprint, robust quality control processes, vibration resistance, and simple, automated cartridge the TEG 6s can be readily deployed in varied settings.

Alongside the TEG 6s hemostasis analyzer, Haemonetics also demonstrated the TEG Manager software that allows secure, real time remote access to patient results, analyzer/user admin & LIS/POC system connectivity. The TEG Manager software system delivers convenient, secure TEG analyzer results viewing and system administration. It provides for robust TEG analyzer data warehousing, real-time, on-demand remote patient results viewing, clinical report generation, LIS connectivity, and user/device management/reporting. The Interpretation Guidance module allows clinicians the option to customize clinical alert messages according to your institution’s guidelines. It displays active and historical TEG results wherever/whenever within the hospital network. It also provides administrative functions including dashboard views of the status of all TEG analyzers throughout the hospital, manage users/access, and a robust suite of operational and audit reporting.

Related Links:
Haemonetics Corporation 


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Urine Analyzer
respons® UDS100
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.